The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies
Open accessAbstract
Summary: Purpose: Three phase III studies (304 [ClinicalTrials.gov identifier: NCT 00699972], 305 [NCT 00699582], 306 [NCT 00700310]) evaluated perampanel, an α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor antagonist, as adjunctive therapy for refractory partial seizures. We report post hoc analyses of pooled study data by randomized dose. Methods: Patients with partial seizures despite receiving 1–3 antiepileptic drugs were randomized to once‐daily placebo, perampanel 8 or 12 mg (studies 304, 305), or placebo, perampanel 2, 4, or 8 mg (study 306). Studies included a 6‐week baseline period and double‐blind treatment phase (6‐week titration; 13‐week maintenance). Primary end points were median change in partial seizure frequency (baseline vs. double‐blind phase) and percentage of patients achieving ≥50% reduction in seizure frequency (baseline vs. maintenance). Here, these end points, together with secondary, exploratory, and safety end points, were assessed using pooled study data. Key Findings: The pooled intent‐to‐treat analysis set (randomized, treated patients with any seizure data) included 1,478 patients. Median changes in partial seizure frequency were greater with perampanel than placebo (perampanel 4 mg, −23.3%; 8 mg, −28.8%; 12 mg, −27.2%; placebo, −12.8%; p < 0.01, each dose vs. placebo), as were 50% responder rates (perampanel 4 mg, 28.5%; 8 mg, 35.3%; 12 mg, 35.0%; placebo, 19.3%; p < 0.05, each dose vs. placebo). In addition, median changes in complex partial plus secondary generalized seizure frequency were also greater with perampanel than placebo (perampanel 4 mg, −31.2%; 8 mg, −35.6%; 12 mg, −28.6%; placebo, −13.9%). Perampanel was generally well tolerated. The most frequent treatment‐emergent adverse events (TEAE s) were dizziness, somnolence, and headache. Most TEAE s were mild/moderate; relatively few patients experienced severe TEAE s (placebo, 5.4%; perampanel, 8.9%) or serious TEAE s (placebo, 5.0%; perampanel, 5.5%). There were no deaths and no clinically important mean changes in laboratory values, electrocardiography (ECG) findings, or vital signs. Significance: Perampanel reduced partial seizure frequency and improved responder rates compared with placebo, with an acceptable tolerability profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304
French, J. A., Krauss, G. L., Biton, V., Squillacote, D., Yang, H., Laurenza, A., Kumar, D., Rogawski, M. A., Campanille, V., Floridia, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635735 · Cited by 479
Self-citationRandomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures
Krauss, G. L., Serratosa, J. M., Villanueva, V., Endziniene, M., Hong, Z., French, J., Yang, H., Squillacote, D., Edwards, H. B., Zhu, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318254473a · Cited by 431
Self-citationRefractory Epilepsy: Clinical Overview
French, J. A. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00992.x · Cited by 430
French, J. A., Krauss, G. L., Steinhoff, B. J., Squillacote, D., Yang, H., Kumar, D., & Laurenza, A. (2013) · Epilepsia · doi:10.1111/j.1528-1167.2012.03638.x · Cited by 423
Self-citationHanada, T., Hashizume, Y., Tokuhara, N., Takenaka, O., Kohmura, N., Ogasawara, A., Hatakeyama, S., Ohgoh, M., Ueno, M., & Nishizawa, Y. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03109.x · Cited by 411
Halász, P., Kälviäinen, R., Mazurkiewicz‐Beldzińska, M., Rosenow, F., Doty, P., Hebert, D., Sullivan, T., & on behalf of the SP755 Study Group (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01951.x · Cited by 392
Revisiting AMPA Receptors as an Antiepileptic Drug Target
Rogawski, M. A. (2011) · Epilepsy Currents · doi:10.5698/1535-7511-11.2.56 · Cited by 316
Antiepileptic drug therapy the story so far
Brodie, M. J. (2010) · Seizure · doi:10.1016/j.seizure.2010.10.027 · Cited by 298
Long‐term social outcomes for children with epilepsy
Camfield, C. S., & Camfield, P. R. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01390.x · Cited by 229
Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy
French, J. A., Abou-Khalil, B. W., Leroy, R. F., Yacubian, E. M. T., Shin, P., Hall, S., Mansbach, H., & Nohria, V. (2011) · Neurology · doi:10.1212/wnl.0b013e3182194bd3 · Cited by 186
Cited by
Krauss, G. L., Klein, P., Brandt, C., Lee, S. K., Milanov, I., Milovanovic, M., Steinhoff, B. J., & Kamin, M. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30399-0 · Cited by 342
Self-citationPerampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial
French, J. A., Krauss, G. L., Wechsler, R. T., Wang, X.-F., DiVentura, B., Brandt, C., Trinka, E., O'Brien, T. J., Laurenza, A., Patten, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001930 · Cited by 329
Self-citationEpilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review
Brodie, M. J., Besag, F., Ettinger, A. B., Mula, M., Gobbi, G., Comai, S., Aldenkamp, A. P., & Steinhoff, B. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012021 · Cited by 288
Self-citationA review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
Metadata
- Authors
- Steinhoff, B. J., Ben‐Menachem, E., Ryvlin, P., Shorvon, S., Kramer, L., Satlin, A., Squillacote, D., Yang, H., Zhu, J., & Laurenza, A.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2013-05-10
- Volume
- 54
- Issue
- 8
- Pages
- 1481-1489
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2145520222
- Cited by
- 268
- References
- 13
- FWCI
- 17.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. https://app.cochat.ai/papers/10.1111/epi.12212
- The paper
- Steinhoff, B. J., Ben‐Menachem, E., Ryvlin, P., Shorvon, S., Kramer, L., Satlin, A., Squillacote, D., Yang, H., Zhu, J., & Laurenza, A. (2013). Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia. https://doi.org/10.1111/epi.12212
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.